Please login to the form below

Not currently logged in
Email:
Password:

GalNAc

This page shows the latest GalNAc news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

This approach will be combined with a liver-targeting delivery technology in development at Pfizer that involves binding RNA drugs to the amno acid N-acetylgalactosamine (GalNAc). ... The deal gives WAVE scope to use GalNAc in certain projects that lie

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    targets. The overt focus on liver disease has led to one new system for delivering siRNA to the liver, called GalNAc. ... GalNAc uses a specific sugar group attached to chemically-modified siRNA to target liver cells.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics